JPWO2024019103A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2024019103A5 JPWO2024019103A5 JP2023567970A JP2023567970A JPWO2024019103A5 JP WO2024019103 A5 JPWO2024019103 A5 JP WO2024019103A5 JP 2023567970 A JP2023567970 A JP 2023567970A JP 2023567970 A JP2023567970 A JP 2023567970A JP WO2024019103 A5 JPWO2024019103 A5 JP WO2024019103A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxy
- indazol
- diazabicyclo
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024020906A JP2024056893A (ja) | 2022-07-21 | 2024-02-15 | Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022116367 | 2022-07-21 | ||
| JP2022116367 | 2022-07-21 | ||
| PCT/JP2023/026522 WO2024019103A1 (ja) | 2022-07-21 | 2023-07-20 | Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020906A Division JP2024056893A (ja) | 2022-07-21 | 2024-02-15 | Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2024019103A1 JPWO2024019103A1 (https=) | 2024-01-25 |
| JP7440710B1 JP7440710B1 (ja) | 2024-02-28 |
| JPWO2024019103A5 true JPWO2024019103A5 (https=) | 2024-06-25 |
Family
ID=89617857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567970A Active JP7440710B1 (ja) | 2022-07-21 | 2023-07-20 | Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物 |
| JP2024020906A Pending JP2024056893A (ja) | 2022-07-21 | 2024-02-15 | Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020906A Pending JP2024056893A (ja) | 2022-07-21 | 2024-02-15 | Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250145631A1 (https=) |
| EP (1) | EP4559906A1 (https=) |
| JP (2) | JP7440710B1 (https=) |
| KR (1) | KR20250036820A (https=) |
| CN (2) | CN119894881A (https=) |
| AR (1) | AR129976A1 (https=) |
| AU (1) | AU2023311603A1 (https=) |
| CA (1) | CA3262030A1 (https=) |
| CL (1) | CL2025000158A1 (https=) |
| CO (1) | CO2025000804A2 (https=) |
| IL (1) | IL317908A (https=) |
| MX (1) | MX2025000772A (https=) |
| TW (1) | TW202409002A (https=) |
| WO (1) | WO2024019103A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025052649A1 (ja) * | 2023-09-08 | 2025-03-13 | アステラス製薬株式会社 | 単一の軸不斉化合物の選択的製造法 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528311A (zh) | 2023-09-13 | 2025-07-16 | 日商安斯泰來製藥股份有限公司 | 包含具有ｇ１２ｄ突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025085815A1 (en) * | 2023-10-20 | 2025-04-24 | Seed Therapeutics Us, Inc. | Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation |
| TW202545930A (zh) * | 2024-01-24 | 2025-12-01 | 日商安斯泰來製藥股份有限公司 | 用於誘導kras蛋白質之分解之雜環化合物 |
| TW202545934A (zh) * | 2024-02-05 | 2025-12-01 | 日商安斯泰來製藥股份有限公司 | 包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體 |
| WO2025168124A1 (zh) * | 2024-02-08 | 2025-08-14 | 杭州多域生物技术有限公司 | 喹唑啉类化合物、其药物组合物及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) * | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| CA3102996A1 (en) | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| CN120698983A (zh) * | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US20230002371A1 (en) * | 2019-09-13 | 2023-01-05 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CN115803030A (zh) | 2020-04-06 | 2023-03-14 | 阿维纳斯企业公司 | 用于kras靶向降解的化合物和方法 |
| WO2022002102A1 (en) | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| WO2022015375A1 (en) | 2020-07-16 | 2022-01-20 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4192585A4 (en) | 2020-08-04 | 2024-08-21 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022098625A1 (en) | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022105855A1 (en) | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| WO2022148422A1 (en) | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| US20240092803A1 (en) | 2021-01-08 | 2024-03-21 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| WO2022173032A1 (ja) | 2021-02-15 | 2022-08-18 | アステラス製薬株式会社 | Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物 |
| CN115260158A (zh) | 2021-04-30 | 2022-11-01 | 上海医药集团股份有限公司 | 一种靶向蛋白调节剂的化合物及其应用 |
| CN117460737A (zh) | 2021-07-05 | 2024-01-26 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
-
2023
- 2023-07-20 US US18/684,845 patent/US20250145631A1/en active Pending
- 2023-07-20 JP JP2023567970A patent/JP7440710B1/ja active Active
- 2023-07-20 CN CN202380067526.9A patent/CN119894881A/zh active Pending
- 2023-07-20 CN CN202511418017.3A patent/CN121449622A/zh active Pending
- 2023-07-20 TW TW112127090A patent/TW202409002A/zh unknown
- 2023-07-20 AR ARP230101905A patent/AR129976A1/es unknown
- 2023-07-20 KR KR1020257002100A patent/KR20250036820A/ko active Pending
- 2023-07-20 AU AU2023311603A patent/AU2023311603A1/en active Pending
- 2023-07-20 WO PCT/JP2023/026522 patent/WO2024019103A1/ja not_active Ceased
- 2023-07-20 IL IL317908A patent/IL317908A/en unknown
- 2023-07-20 EP EP23843026.8A patent/EP4559906A1/en active Pending
- 2023-07-20 CA CA3262030A patent/CA3262030A1/en active Pending
-
2024
- 2024-02-15 JP JP2024020906A patent/JP2024056893A/ja active Pending
-
2025
- 2025-01-17 CL CL2025000158A patent/CL2025000158A1/es unknown
- 2025-01-20 MX MX2025000772A patent/MX2025000772A/es unknown
- 2025-01-27 CO CONC2025/0000804A patent/CO2025000804A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2024019103A5 (https=) | ||
| Heravi et al. | Prescribed drugs containing nitrogen heterocycles: an overview | |
| HRP20231310T1 (hr) | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene | |
| RU2006124026A (ru) | Гетероциклические агенты против мигрени | |
| RU2005122932A (ru) | Производные бензазепина для лечения неврологических нарушений | |
| JP2007501189A5 (https=) | ||
| JP2006500348A5 (https=) | ||
| JP2024502433A5 (https=) | ||
| Costantino et al. | Designed multiple ligands: basic research vs clinical outcomes | |
| CA2587642A1 (en) | Substituted heterocycles and methods of use | |
| RU2407740C2 (ru) | Гетеробициклические сульфонамидные производные для лечения диабета | |
| US9403830B2 (en) | Inhibitors of leukotriene production | |
| RU2497813C2 (ru) | 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение | |
| JP2008525502A5 (https=) | ||
| JP2006512412A5 (ja) | 神経系の疾患の治療用のベンズアゼピン誘導体 | |
| JP2014532619A5 (https=) | ||
| JP2018524343A5 (https=) | ||
| RU2018105684A (ru) | Замещенные трициклические соединения и способ применения | |
| JP2011527665A5 (https=) | ||
| RU2382778C2 (ru) | Производные индола в качестве антагонистов гистаминовых рецепторов | |
| JP2005527590A5 (https=) | ||
| RU2005134006A (ru) | Производные 4-(4-{гетероциклилалкокси}фенил0-1-(гетероциклилкарбонил)пиперидина и родственные соединения как антагонисты гистамина н3 для лечения неврологических заболеваний, таких как болезнь альцгеймера | |
| JP2006528940A5 (https=) | ||
| JP2010513304A5 (https=) | ||
| HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze |